Inventprise Inc.
Inventprise is a biopharmaceutical company dedicated to developing innovative vaccines against infectious diseases, with a focus on global health. They leverage proprietary platform technologies to create high-valency vaccines that induce broad, robust, and durable protection. Their mission is to empower people worldwide to live healthy lives by inventing better vaccines, and they are actively involved in research, development, manufacturing, and clinical trials of vaccines for diseases such as pneumococcal disease, GBS, Shigella, and SARS-CoV-2. The company emphasizes a people-first philosophy, fostering a diverse and inclusive culture, and collaborates with global health organizations to improve vaccine access and coverage.
Industries
Nr. of Employees
medium (51-250)
Inventprise Inc.
18133 NE 68th D150, Redmond, WA 98052
Patents
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US-12053515-B2
View Details
Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
US-12053515-B2
View DetailsProducts
25-valent pneumococcal conjugate vaccine candidate (high-valency PCV)
Investigational 25-serotype pneumococcal conjugate vaccine developed to broaden coverage against pneumococcal disease in pediatric and other at-risk populations; progressed into Phase 1/2 and Phase 2 clinical studies.
mRNA vaccine development programs (example: RSV mRNA candidate)
mRNA vaccine development using GMP-grade, scalable, automated mRNA production systems to support rapid development and scalable manufacture for respiratory viral targets.
Pipeline vaccine candidates (bacterial and viral targets)
Investigational vaccine programs targeting pathogens such as group B streptococcus (GBS), Shigella, Klebsiella and additional viral targets, advanced through R&D and early clinical development.
25-valent pneumococcal conjugate vaccine candidate (high-valency PCV)
Investigational 25-serotype pneumococcal conjugate vaccine developed to broaden coverage against pneumococcal disease in pediatric and other at-risk populations; progressed into Phase 1/2 and Phase 2 clinical studies.
mRNA vaccine development programs (example: RSV mRNA candidate)
mRNA vaccine development using GMP-grade, scalable, automated mRNA production systems to support rapid development and scalable manufacture for respiratory viral targets.
Pipeline vaccine candidates (bacterial and viral targets)
Investigational vaccine programs targeting pathogens such as group B streptococcus (GBS), Shigella, Klebsiella and additional viral targets, advanced through R&D and early clinical development.
Services
Process and analytical development to optimize protein and conjugation processes for clinical and commercial readiness.
Small- and large-scale GMP manufacturing including continuous manufacturing readiness, fill/finish, and 24/7 process monitoring to supply clinical trials and commercial demand.
Quality system design, validation support, and regulatory programming to facilitate regulatory submissions and product approvals.
Design and implementation of integrated automation and digital strategies aligned with industry control frameworks to enable observability and continuous processing.
Process and analytical development to optimize protein and conjugation processes for clinical and commercial readiness.
Small- and large-scale GMP manufacturing including continuous manufacturing readiness, fill/finish, and 24/7 process monitoring to supply clinical trials and commercial demand.
Quality system design, validation support, and regulatory programming to facilitate regulatory submissions and product approvals.
Design and implementation of integrated automation and digital strategies aligned with industry control frameworks to enable observability and continuous processing.
Expertise Areas
- Conjugate vaccine development
- High-valency vaccine design
- Clinical trial management (Phase 1–2)
- GMP biologics and vaccine manufacturing
Key Technologies
- Hydrazide-PEG-Hydrazide linker chemistry
- Conjugation chemistry for glycoconjugate vaccines
- Continuous manufacturing
- Manufacturing automation (ISA-95 / ISA-88)
News & Updates
Inventprise announced the selection of Quantoom Biosciences’ Ntensify midi system to support its mRNA vaccine platform, enhancing rapid development and scalability.
Announcement of new board members from leading companies in Washington state’s life sciences industry, including Yves Leurquin of Inventprise.
The company announced the completion of vaccination in a Phase 2 study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25).
A Phase 1/2 clinical study of IVT PCV-25 has begun to evaluate safety and immune response, aiming to expand protection against pneumococcal disease.
Recent news articles about Inventprise and its vaccine development efforts.
Latest updates and news releases from Inventprise.
Inventprise announced the selection of Quantoom Biosciences’ Ntensify midi system to support its mRNA vaccine platform, enhancing rapid development and scalability.
Announcement of new board members from leading companies in Washington state’s life sciences industry, including Yves Leurquin of Inventprise.
The company announced the completion of vaccination in a Phase 2 study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25).
A Phase 1/2 clinical study of IVT PCV-25 has begun to evaluate safety and immune response, aiming to expand protection against pneumococcal disease.
Recent news articles about Inventprise and its vaccine development efforts.
Latest updates and news releases from Inventprise.